Dallas, Texas 75235

  • Major Depressive Disorder

Purpose:

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.


Criteria:

Inclusion Criteria: - Have a diagnosis of moderate to severe major depressive disorder - Currently taking a SSRI, SNRI, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks - Must have failed to adequately respond to the current antidepressant medication - Willing to comply with all study assessments and procedures - Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: - Evidence of liver impairment or disease - Active suicidal ideation - Moderate to severe Alcohol Use Disorder - Diagnosed bipolar disorder or psychotic disorder - Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients - Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device


NCT ID:

NCT05118750


Primary Contact:

Jillian Autea
Phone: 650-397-5693
Email: jillianautea@altoneuroscience.com


Backup Contact:

Email: lparker@altoneuroscience.com
Lesley Parker


Location Contact:

Dallas, Texas 75235
United States

Dharma

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.